Brought to you by 
Series D financing gives TargeGen $40mm
19 Jul 2007
Executive Summary
TargeGen (developing small molecules for vascular function diseases such as macular degeneration) closed a fully subscribed $40mm Series D round. First-time backers Innovis Investments, VantagePoint Venture Partners, and CTI Life Sciences Fund were joined by returning investors including Forward Ventures, Enterprise Partners, Chicago Growth Partners/William Blair Capital Partners, CDP Capital, BB Biotech, Hambrecht & Quist Capital Management, and Pappas Ventures. The company added an executive from Innovis to its board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D financing gives TargeGen $40mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice